MetaCap

Incannex Healthcare (IXHL) vs TransCode Therapeutics (RNAZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Incannex Healthcare (IXHL) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 80.3% versus a loss of 86.6%. Incannex Healthcare is the larger company by market cap ($23.3 million vs $20.1 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IXHL-80.32%RNAZ-86.57%
+59%-17%-94%
Nov 21, 20251 yearNov 20, 2026
IXHL-99.88%RNAZ-100.00%
+42%-32%-107%
Feb 28, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IXHL versus RNAZ key metrics
MetricIXHLRNAZ
Share price$1.86$1.16
Market cap$23.34M$20.07M
1-day change+6.90%-10.77%
YTD return-82.68%-83.02%
1-year return-80.32%-86.57%
5-year return—-100.00%
EPS (TTM)$-1.25$-47.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-19.30M$-34.66M
52-week high$14.91$12.60
52-week low$1.61$1.01
Distance from 52-week high-87.53%-90.79%
Analyst consensusstrong_buy—
Avg. price target upside+904.30%—
Average volume91.61K52.03K
Shares outstanding12.55M17.30M
Employees1212
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Incannex Healthcare

IXHL stock →

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About TransCode Therapeutics

RNAZ stock →

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

IXHL vs RNAZ FAQ

Which is bigger, Incannex Healthcare or TransCode Therapeutics?

Incannex Healthcare (IXHL) is larger, with a market capitalization of $23.34M compared with $20.07M for TransCode Therapeutics (RNAZ).

Which stock has performed better over the past year, IXHL or RNAZ?

IXHL returned -80.32% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.

Are Incannex Healthcare and TransCode Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons